Cetylated fatty acids

Cetylated Fatty Acids

1. Identity: Chemical Names, Natural Sources, and Common Preparations

1.1 Definition and Chemical Identity

Cetylated fatty acids (CFAs) comprise a group of naturally occurring fatty acids from vegetable origin. This group includes compounds such as cetyl myristate, cetyl palmitate, and cetyl oleate, among others. More precisely, CFAs are a group of esterified fatty acids administered either topically or orally to protect the synovial membrane and stabilize cell membranes.

The defining structural feature of CFAs is the esterification of a fatty acid with cetyl alcohol (1-hexadecanol, a 16-carbon saturated alcohol), producing long-chain fatty acid esters. The key individual constituents of commercial CFA formulations have been identified as:

• Cetyl myristoleate (cetyl cis-9-tetradecenoate) — a C16 alcohol esterified with myristoleic acid (C14:1 Δ9). Also called cetyl myristoleate or CMO. This is the compound originally isolated from Swiss albino mice and the best-studied single constituent.
• Cetyl myristate — cetyl alcohol esterified with myristic acid (C14:0).
• Cetyl palmitate — cetyl alcohol esterified with palmitic acid (C16:0).
• Cetyl palmitoleate — cetyl alcohol esterified with palmitoleic acid (C16:1).
• Cetyl oleate — cetyl alcohol esterified with oleic acid (C18:1).
• Cetyl laurate — cetyl alcohol esterified with lauric acid (C12:0).

The patented Celadrin formulation is a combination of cetylated, esterified fatty acids containing cetyl myristoleate, cetyl myristate, cetyl palmitoleate, cetyl laureate, cetyl palmitate, and cetyl oleate, extracted from plant-based sources, with oils including palm, palm kernel, olive, nutmeg, coconut, and unsaturated vegetable oils.

The common name for the single-compound precursor is cetyl myristoleate (CMO), whose systematic name is cis-9-cetyl myristoleate. Cetyl myristoleate can be synthesized chemically: it has been prepared by an esterification reaction between myristoleic acid and cetyl alcohol, catalyzed by p-toluenesulfonic acid monohydrate.

1.2 Natural Sources

Cetylated fatty acids are a group of naturally occurring fats of plant and/or animal origin. The founding compound, cetyl myristoleate, is found naturally in animals. Cetyl myristoleate was isolated for the first time by Dr. Harry Diehl at the Laboratory of Chemistry of the National Institute of Arthritis, Metabolic, and Digestive Diseases in Bethesda, Maryland. Dr. Diehl had tried to unsuccessfully induce polyarthritis in Swiss albino mice using Freund's adjuvant (heat-killed desiccated Mycobacterium butyricum) but realized that they were immune. Further investigation revealed that cetyl myristoleate was what was causing the mice to be immune to becoming arthritic.

Commercial CFA supplements, however, are predominantly derived from vegetable oils rather than animal tissues. The plant-based sources include palm, palm kernel, olive, nutmeg, coconut, and other unsaturated vegetable oils, from which the individual fatty acids are extracted and then esterified with cetyl alcohol. This dietary supplement is believed to work in a similar way to the essential fatty acids from fish oil, enhancing the cell membrane integrity and reducing inflammation.

1.3 Common Preparations and Dosage Forms

CFAs are available in several delivery forms that have been used in published studies:

• Oral capsules/gel: The most widely studied oral form uses 350 mg capsules or a 1.5 g oral gel preparation. At least one European clinical study evaluated a CFAs-based food supplement containing a mixture of vegetable-derived fatty acids esterified with cetyl alcohol (Lipocet®), formulated as an oral gel (Cetilar® ORO, PharmaNutra S.p.A., Italy).
• Topical cream: Creams incorporating CFAs (often as a percentage blend) applied directly to the skin over affected joints. The Celadrin cream and analogous branded formulations are the most frequently studied.
• Transdermal patch: A patch containing CFA (Cetilar® Patch, Pharmanutra SpA, Pisa, Italy), worn for 8 hours a day for consecutive days, has been studied in shoulder tendinopathy.

Since their introduction in 2004, CFA products have been primarily marketed for joint health. Dosages typically range from 1,000 to 2,000 milligrams daily when taken orally, or through topical application of creams multiple times a day.

2. Historical Discovery and Background

Unlike most botanical dietary supplements with centuries of traditional use, cetylated fatty acids as a defined supplement category have an entirely modern scientific origin. There is no record of traditional or ethnobotanical use of CFAs per se; the supplement category emerged directly from laboratory research in the twentieth century.

Cetyl myristoleate was first identified in the 1970s by Dr. Harry W. Diehl, a researcher at the Laboratory of Chemistry of the National Institute of Arthritis, Metabolic, and Digestive Diseases (now part of the National Institute of Diabetes and Digestive and Kidney Diseases) in Bethesda, Maryland. Diehl's work focused on understanding why certain animals, particularly Swiss albino mice, resisted arthritis induction, while others like rats were susceptible.

In initial experiments, researchers attempted to induce polyarthritis in National Institutes of Health general-purpose Swiss albino mice through subcutaneous injection of Freund's adjuvant, consisting of heat-killed, desiccated Mycobacterium butyricum suspended in light mineral oil. Unexpectedly, the mice remained immune, showing no signs of leg or paw swelling even after 10–20 days, unlike susceptible species.

The compound was isolated and identified using thin layer chromatography. Diehl's work led to the issuance of two U.S. patents on cetyl myristoleate — one in 1977 and a second in 1996. His findings were published in the Journal of Pharmaceutical Sciences in March 1994, a peer-reviewed publication of the American Pharmaceutical Association and the American Chemical Society.

Cetyl myristoleate has been available over-the-counter in the United States as a dietary supplement since the 1990s, following its initial discovery and patenting in the 1970s. In 2001, a new formulation containing a cetylated fatty ester complex (CFEC; also known as esterified fatty acid complex or EFAC) began to be used for arthritic and sports injury-related conditions. In 2004, a special mixture of fats called cetylated fatty acids began to be widely marketed as a treatment for osteoarthritis.

3. Key Constituents and Mechanisms of Action

3.1 Principal Active Compounds

The CFA complex is not a single molecule but a mixture of long-chain fatty acid esters. The series of unsaturated CFAs generally display higher biological potencies than most saturated derivatives. In particular, cetyl myristoleate (CMO), whose anti-arthritis properties had been previously demonstrated in murine models, proved to efficiently inhibit the enzyme monoacylglycerol lipase (MAGL). Similarly, its close analogue cetyl palmitoleate proved to be equally active, whereas cetyl oleate displayed slightly weaker potency, probably due to the extended length of its acyl chain encountering some steric interaction with the enzyme active site.

3.2 Proposed Mechanisms of Action

The precise mechanism of action of CFAs' analgesic and anti-inflammatory properties has not yet been clearly established. Several partly overlapping mechanisms have been proposed and investigated:

3.2.1 Endocannabinoid System Modulation (MAGL Inhibition)

A 2025 biochemical investigation proposed a new mechanistic explanation. Endocannabinoids such as 2-arachidonoylglycerol (2-AG) and anandamide (AEA) are known to produce analgesic and anti-inflammatory effects. These compounds undergo physiological inactivation by several enzymes, including monoacylglycerol lipase (MAGL). The study demonstrated for the first time that the therapeutic effects of CFAs may be attributable, at least in part, to their MAGL inhibition activities, which induce a local increase in analgesic/anti-inflammatory endocannabinoids in close proximity to the site of administration. These findings pave the way for the development of new potent local analgesic agents whose action is based on an indirect cannabinoid effect. It must be noted that this evidence is preclinical and biochemical in nature.

3.2.2 Suppression of Pro-inflammatory Cytokines

In vitro work has shed light on the anti-inflammatory activity of CFA mixtures. The cetylated fatty acids mixture from Celadrin significantly decreased the production of IL-6, MCP-1, and TNF — key regulators of the inflammatory process — in stimulated RAW264.7 mouse macrophage cells. These reductions in cytokine production mirror properties attributed to classical anti-inflammatory agents. In vitro studies suggest that CFAs stimulate chondrogenesis while downregulating pro-inflammatory cytokines such as TNF-α and IL-6.

3.2.3 Promotion of Chondrogenesis

The treatment with cetylated fatty acids mixture initiated and propagated the process of chondrogenesis, as demonstrated by the increased expression and deposition of chondrogenic markers by differentiating mesenchymal cells. Specifically, these compounds facilitate the chondrogenic differentiation process of human adipose-derived stem cells by stimulating the expression of chondrogenic markers under chondrogenic induction conditions. This finding is entirely in vitro and has not been confirmed in human tissues or clinical settings.

3.2.4 Synovial Membrane Protection and Cell Membrane Stabilization

CFAs have been shown to play a role in synovial membrane protection and cell membrane stabilization, promoting normal flexibility and mobility, leading to a reduction in pain and an increase in joint fluidity and lubrication. This lubrication hypothesis is supported by clinical observations but its direct cellular basis remains incompletely characterized.

3.2.5 Classical Fatty-Acid Anti-inflammatory Pathways

Fatty acids may induce changes in membrane fluidity, antibody and cytokine production, adhesion molecule expression, and signal transduction pathways, suppress leukocyte function, trigger apoptosis, and — like NSAIDs — reduce production of prostaglandins and leukotrienes. These mechanisms are not unique to CFAs and are shared with other bioactive fatty acid families, but may contribute to the observed effects of cetylated esters.

4. Scientific Evidence by Area of Use

4.1 Knee Osteoarthritis

The largest and most consistent body of clinical evidence for CFAs concerns knee osteoarthritis (OA). Evidence ranges from individual randomized controlled trials (RCTs) to a 2026 systematic review and meta-analysis.

Oral CFA — Placebo-Controlled RCTs

The foundational oral study was conducted by Hesslink et al. (2002). Sixty-four patients with chronic knee OA were evaluated at baseline and at 30 and 68 days after consuming either placebo (vegetable oil; n = 31) or CFA (Celadrin; n = 33). Evaluations included physician assessment, knee range of motion with goniometry, and the Lequesne Algofunctional Index (LAI). After 68 days, patients treated with CFA exhibited a significant (p < 0.001) increase in knee flexion (10.1 degrees) compared to patients given placebo (1.1 degrees). Neither group reported improvement in knee extension. Patient responses to the LAI indicated a significant (p < 0.001) shift towards functional improvement for the CFA group (−5.4 points) after 68 days, compared to a modest improvement in the placebo group (−2.1 points). In this study, the CFA combination was administered at six capsules or 2.1 g per day.

A 2023 parallel-arm RCT compared oral CFA with meloxicam in 48 adults with knee OA. The intervention group was prescribed 350 mg CFA capsules three times per day for 30 days. The control group was given 15 mg of meloxicam, one tablet daily for ten days. In the group treated by oral CFA, improvements in physical function as measured by the WOMAC questionnaire were observed at two, four, and eight weeks compared to baseline. Patients in the oral CFA group also reported less pain on the VAS and the pain subscale of the WOMAC questionnaire at the same time points. This study was limited by its active comparator design (rather than placebo control) and the much shorter duration of meloxicam treatment (10 days vs. 30 days for CFA), which restricts direct head-to-head interpretation.

A 2025 double-blind, placebo-controlled RCT enrolled 60 patients with grade 3–4 knee OA. Patients (mean age 66.0 ± 7.7 years, 85% female) with pain intensity > 4 cm on VAS were randomized 1:1 to receive either 1.5 g of oral CFA or placebo for 60 days. After 60 days, the mean reduction in pain intensity (VAS) was −1.7 cm (95% CI [−2.0, −1.4]), showing a statistically significant difference compared to placebo (−0.6 cm, 95% CI [−1.0, −0.2]; p < 0.005). The mean decrease in the WOMAC total score was also greater in the CFA group (−19.5 vs. −15.8), although the placebo-corrected effect was not statistically significant (−3.7, 95% CI [−8.3, 0.8]; p = 0.108).

Topical CFA — Placebo-Controlled RCTs

Kraemer et al. (2004) examined the effect of a topical CFA cream in 40 knee OA patients. Forty patients diagnosed with knee OA were randomly assigned to one of two topical treatment groups: (1) cetylated fatty acid (CFA) (n = 20; age 62.7 ± 11.7 yrs) or (2) placebo (n = 20; age 64.6 ± 10.5 yrs). Patients were tested on three occasions: baseline (T1), 30 minutes after initial treatment (T2), and after a 30-day treatment of cream applied twice per day (T3). The study, published in the Journal of Rheumatology, found significant improvements in functional performance and quality of life in the CFA group.

A subsequent 2005 study by Kraemer et al. extended this work to examine postural stability. Forty patients diagnosed with knee OA were randomly assigned to either cetylated fatty acid cream (N = 20) or placebo (N = 20). Patients were tested at baseline and following a 30-day treatment period of cream application twice per day. Assessments included 20- and 40-second quiet standing protocols on a force plate to measure center of pressure (COP) total excursion length, COP velocity, and rearfoot and forefoot plantar pressure distribution. In the CFA group, a significant reduction in COP excursion length and velocity was observed.

An Italian multicenter study examined 113 knee OA patients. The study included 113 patients (32 males, 81 females; median age 70.0 years) with knee OA diagnosed according to American College of Rheumatology classification criteria. Each patient underwent knee X-rays, followed by a CFA topical treatment (two applications per day for one week). Before and after the treatment, patients completed a WOMAC questionnaire. This was a pre-post study without a parallel placebo arm, limiting causal interpretation.

Systematic Review and Meta-Analysis (2026)

The most comprehensive synthesis of the evidence to date was published in Clinical and Experimental Rheumatology in January 2026. The authors conducted a comprehensive search in PubMed, Embase, Cochrane Library, CENTRAL, and Web of Science from inception until November 2024 to examine the therapeutic effects of CFAs. They included RCTs with a CFA intervention group compared with a control group that received either a placebo or a non-CFA treatment, as well as pre-post experimental studies. The review concluded that CFAs may improve pain levels, knee range of motion, and physical function in patients with knee OA, particularly the oral form. Further research is required to determine the synergistic effects as a supplementary regimen, longer-term effects, and safety profiles.

4.2 Hand Osteoarthritis

Evidence in hand OA is more limited. Prior to 2025, there were no published studies on CFAs specifically in OA of the hand. The only randomized controlled trial to evaluate topical CFA therapy in hand OA was conducted in 72 patients with symptomatic CMC or IP joint involvement. Patients fulfilling the American College of Rheumatology criteria for hand OA participated. Eligible patients were over 40 years of age, had at least one tender joint, and had a joint pain VAS score of 30–60 mm. Patients received topical CFA (n = 36) or placebo (n = 36) twice daily for six weeks. The primary outcome was the Functional Index for Hand Osteoarthritis (FIHOA) at 2, 4, and 6 weeks. FIHOA scores in both groups exhibited a progressive decrease over time. No discernible distinctions were observed between the CFA and placebo cohorts at the 2-week interval following cream application. However, noteworthy differences emerged at later time points. Published in Scientific Reports in 2025, this constitutes the first and only RCT in this indication, and broader conclusions await replication in larger trials.

4.3 Shoulder Tendinopathy

A prospective, single-center, non-profit observational study evaluated the efficacy and tolerability of a CFA patch formulation in the control of acute localized shoulder pain and recovery of function in patients with tendinopathies. Thirty patients with recent onset shoulder pain symptoms (1–3 months) related to bursitis and tenosynovitis, with ultrasound-confirmed shoulder tendon pathology, were evaluated using the Constant–Murley Score. Patients used one patch containing CFA for 8 hours per day for 10 days. This study was published in BMC Musculoskeletal Disorders (2022). As an uncontrolled single-arm observational study, it provides only preliminary, low-certainty evidence. There is no available prior study dealing with CFA for shoulder tendinopathy, making this the only published data in this indication.

4.4 Elbow and Wrist Pain

Individuals diagnosed with OA of the elbow (N = 8; age 59.1 ± 18.2 years) and wrist (N = 10; age 60.3 ± 16.8 years) were tested for pain and functional performance before and after one week of treatment with a topical cream consisting of cetylated fatty acids and menthol applied twice per day. In individuals with knee OA, significant improvements in stair-climbing ability (about 12%), "up-and-go" performance (about 12%), balance and strength (about 16.5%), and range of motion (about 3.5%) were observed, as were reductions in pain. The study by Kraemer et al. (2005) used a pre-post design without a concurrent placebo arm for the elbow and wrist groups, limiting interpretation. While efficacy has been explored in knee, elbow, and wrist OA, data on effects in hand OA remain sparse.

4.5 Myofascial Pain Syndrome of the Neck

In 2001, a new formulation containing cetylated fatty ester complex (CFEC) began to be used for arthritic and sports injury-related conditions. A study published in the Journal of Bodywork and Movement Therapies (2011) examined the effects of cetylated fatty esters combined with physical therapy in patients with myofascial pain syndrome of the neck. Administration of CFA improved muscle strength and mobility and decreased pain in this context. This study was limited in design and the evidence is preliminary.

4.6 Lumbar Discogenic Pain

A recently published study showed that a four-week oral administration of CFA in patients with axial discogenic lumbar pain decreased disability and pain with minimal adverse effects. This represents only a single study and evidence is preliminary.

4.7 Broader Musculoskeletal Pain (Real-World Evidence)

A real-world observational study was conducted to evaluate decrease in pain after 30-day administration of a new oral CFA food supplement and assess if decreased pain resulted in lower consumption of oral NSAIDs and improvement in related gastric side effects. It was the first study of this food supplement in a real-world setting. One hundred and twenty Italian primary care physicians recruited 562 patients who were prescribed oral CFA. Patients completed the Brief Pain Inventory (BPI) questionnaire at baseline and after 30 days of dosing. The new food supplement containing plant-based CFAs was marketed in Italy since 2022 and appears to be a promising nutritional strategy for managing musculoskeletal pain of various origins. As an observational study without a control group, this design cannot establish causality, and results may be confounded by natural disease course, concomitant therapies, or expectation effects.

4.8 Autoimmune and Other Conditions (Proposed, Minimal Evidence)

Cetylated fatty acids are also used for other types of arthritis including rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis, or for autoimmune diseases like multiple sclerosis, Sjogren's syndrome, and systemic lupus. Supplementation with cetylated fatty acids has been suggested for patients with autoimmune diseases, such as Sjogren's syndrome, lupus, and multiple sclerosis. However, no peer-reviewed human clinical trials specifically evaluating CFAs in these conditions could be identified from the available literature. Claims in these areas are speculative and lack clinical trial support.

4.9 Preclinical (Animal) Evidence

Cetyl myristoleate, in particular, was initially involved in osteoarthritis-related research as its therapeutic administration prevented experimentally induced arthritis in Swiss albino mice. In animal studies, cetyl myristoleate was first reported to block inflammation and prevent adjuvant-induced arthritis at very high doses in rats. In follow-up studies in mice, a modest anti-inflammatory effect was observed. These preclinical findings provided the initial rationale for human studies but cannot themselves be used to predict clinical efficacy or optimal dosing.

5. Body Systems and Health Areas Associated with CFAs

Based on the published evidence reviewed, CFAs have been studied or proposed in relation to the following body systems and health areas:

• Musculoskeletal system / joints: The primary focus, including osteoarthritis of the knee, hand, elbow, and wrist; tendinopathies of the shoulder; and myofascial pain syndromes.
• Connective tissue: Proposed effects on cartilage through chondrogenic differentiation of stem cells, and on the integrity of the synovial membrane.
• Inflammatory and immune pathways: Modulation of cytokines (IL-6, TNF, MCP-1), prostaglandin and leukotriene synthesis, and macrophage activation, with proposed effects on immune-mediated inflammatory diseases.
• Nervous system (pain signaling): Via indirect endocannabinoid pathway modulation (MAGL inhibition) and cell-membrane-mediated effects on peripheral pain processing.
• Spinal / axial structures: Preliminary evidence in lumbar discogenic pain.

6. Dosage Forms and Dosages Reported in Studies

The following dosages and regimens have been reported in published clinical studies. These are presented as reported and do not represent recommendations.

• Oral (Hesslink et al., 2002): Six capsules or 2.1 g per day for 68 days (knee OA).
• Oral (Mohebi et al., 2023): 350 mg CFA capsule three times per day (1,050 mg/day) for 30 days (knee OA).
• Oral (Zodeleva et al., 2025): 1.5 g oral CFA gel per day for 60 days (grade 3–4 knee OA).
• Topical cream (Kraemer et al., 2004): Applied twice per day for 30 days (knee OA).
• Topical cream with menthol (Kraemer et al., 2005): Applied twice per day for one week (knee, elbow, and wrist OA/arthritis).
• Topical cream (Suwannaphisit et al., 2025): Applied twice daily for six weeks (hand OA).
• Transdermal patch (Lanzisera et al., 2022): One patch for 8 hours per day for 10 consecutive days (shoulder tendinopathy).

7. Safety Considerations

7.1 General Tolerability Profile

Numerous studies have shown the effectiveness of topically administered cetylated fatty acids in improving joint mobility, functionality, strength and endurance, as well as reducing pain symptoms in the absence of side effects. Safety studies suggest a low toxicity level; however, more research is needed to establish safe usage parameters, especially for vulnerable populations.

The 2025 oral RCT (Zodeleva et al.) assessed safety as a secondary endpoint. In patients with knee osteoarthritis, incorporating a CFA oral supplement into the treatment regimen provided superior efficacy in pain relief and range of motion improvement compared to placebo, while maintaining a favorable safety profile.

7.2 Potential for NSAID Reduction

One real-world observational study specifically aimed to assess whether decreased pain following oral CFA administration resulted in lower consumption of oral NSAIDs and improvement in related gastric side effects. The potential for CFA to reduce reliance on NSAIDs was an explicit secondary aim, though this hypothesis requires confirmation in controlled trials.

7.3 Patch and Topical Formulation Safety

The shoulder tendon patch study explicitly included known hypersensitivity to CFA or to one of the product excipients as an exclusion criterion, indicating that contact hypersensitivity is a recognized, if presumably rare, risk with topical preparations. Injured skin at the application site was also an exclusion criterion in that study.

7.4 Limitations of the Safety Evidence Base

Further research is required to determine the synergistic effects as a supplementary regimen, longer-term effects, and safety profiles of CFAs in patients with knee OA. The overall body of safety data is limited by relatively small study populations, short trial durations (mostly 30–68 days for oral use), and the absence of dedicated long-term safety studies or pharmacovigilance data. No published clinical trials have systematically examined interactions between CFAs and specific medications, nor have they been studied in pregnant or breastfeeding populations, pediatric patients, or individuals with significant hepatic or renal impairment.

8. Summary of Evidence Strength

The evidence base for CFAs, while growing, remains relatively limited compared to more extensively studied joint-health supplements such as glucosamine or omega-3 fatty acids. The evidence is strongest for topical and oral CFA in knee OA, supported by multiple small-to-moderate RCTs and a 2026 systematic review and meta-analysis concluding that CFAs may improve pain levels, knee ROM, and physical function in patients with knee OA, particularly the oral form. For all other indications — hand OA, shoulder tendinopathy, elbow/wrist OA, neck myofascial pain, lumbar pain, and autoimmune conditions — the evidence is preliminary, based on single small studies, uncontrolled designs, or no human data at all.

While some proponents claim that cetylated fatty acids can reduce inflammation and protect joint health, the scientific support for these claims remains sparse, and there have been no direct comparisons with other supplements like glucosamine. The mechanism of action of CFAs' analgesic and anti-inflammatory properties has not yet been clearly established, though recent biochemical work has proposed MAGL inhibition and endocannabinoid pathway modulation as plausible mechanisms.

References

• Hesslink R Jr, Armstrong D, Nagendran MV, Sreevatsan S, Barathur R. Cetylated fatty acids improve knee function in patients with osteoarthritis. J Rheumatol. 2002;29(8):1708–1712. PubMed PMID: 12180734.
• Kraemer WJ, et al. Effect of a cetylated fatty acid topical cream on functional mobility and quality of life of patients with osteoarthritis. J Rheumatol. 2004;31(4):767–774. PubMed PMID: 15088305.
• Kraemer WJ, et al. A cetylated fatty acid topical cream with menthol reduces pain and improves functional performance in individuals with arthritis. J Strength Cond Res. 2005;19(2):475–480. PubMed PMID: 15903393.
• Kraemer WJ, et al. Effects of treatment with a cetylated fatty acid topical cream on static postural stability and plantar pressure distribution in patients with knee osteoarthritis. J Strength Cond Res. 2005;19(1):115–121. PubMed PMID: 15705022.
• Hudita A, et al. In Vitro Effects of Cetylated Fatty Acids Mixture from Celadrin on Chondrogenesis and Inflammation with Impact on Osteoarthritis. Cartilage. 2020. PMC6921950.
• Bononi G, Granchi C, Tuccinardi T, Minutolo F. Identification of a Possible Endocannabinoid-Mediated Mechanism of Action of Cetylated Fatty Acids. Biomolecules. 2025;15(3):363. PMC11940079.
• Suwannaphisit S, et al. Impact of topical cetylated fatty acid cream on hand osteoarthritis: a randomized, double-blind clinical trial. Sci Rep. 2025;15(1):4587.
• Zodeleva M, et al. Effects of orally administered cetylated fatty acids on symptoms and functional capacity in patients with knee osteoarthritis: results of a randomized, double-blind, placebo-controlled study. Eur J Clin Nutr. 2025. PMC12580315.
• Mohebi S, et al. An Oral Form of Cetylated Fatty Acids versus Meloxicam for Knee Osteoarthritis: A Randomised Clinical Trial. Mediterr J Rheumatol. 2023;34(4):460–468. PMC10815532.
• Tung KM, et al. Effects of cetylated fatty acids on knee osteoarthritis: a systematic review and meta-analysis of real-world evidence. Clin Exp Rheumatol. 2026;44(1):77–86.
• Short-Term Effect of Topical Cetylated Fatty Acid on Early and Advanced Knee Osteoarthritis: A Multi-Center Study. Arch Rheumatol. 2018;33(4). PMC6409167.
• Lanzisera R, et al. A prospective observational study on the beneficial effects and tolerability of a cetylated fatty acids (CFA) complex in a patch formulation for shoulder tendon disorders. BMC Musculoskelet Disord. 2022;23(1):352.
• A Real-World Study of Cetylated Fatty Acids Food Supplement Administration in Italian Adults for Sub-Acute or Chronic Musculoskeletal Pain. PMC12132066.
• Sharan D, et al. The effect of cetylated fatty esters and physical therapy on myofascial pain syndrome of the neck. J Bodyw Mov Ther. 2011;15(3):363–374.
• Wikipedia. Cetyl myristoleate. (Used for contextual background on chemical identity and isolation history.)
• EBSCO CAM Review Board. Cetylated fatty acids as therapeutic supplements. EBSCO Research Starters.